The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating Datroway compared to docetaxel in patients with TROP2 NMR positive locally advanced or metastatic nonsquamous non-small cell lung cancer without actionable genomic alterations previously treated with immunotherapy and platinum-based chemotherapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (AZN).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca Deepens Respiratory Pipeline With New China-Focused Bronchiectasis Study
- AstraZeneca’s Real‑World Tezepelumab Study in Spain: What Investors Should Watch
- Walmart to become component of Nasdaq-100 Index
- Tempus AI (TEM) Tops $1.1B in Total Contract Value as Pharma Demand for AI Tools Surges
- AstraZeneca’s DAHLIA Lupus Study: Real‑World Data Could Strengthen Anifrolumab’s Long‑Term Investment Case